Biocon Joins March Into China With CMS
Biocon has joined the march of Indian firms into China, tying up with Chinese firm CMS to sell three generic formulations in the world’s second-largest drug market.
You may also be interested in...
Also, deals involving Immunomic, Replicate, Biocon, DKSH, Genor, G1, Daiichi Sankyo, Esperion, Alteogen, Gelesis, China Medical System Holdings, Sosei and EverInsight.
Deal news from GeoVax/BravoVax, Onconova/HanX, Zydus Cadila/China Medical System Holdings, EyePoint/Ocumension, Ningbo NewBay Medical/Genentech, Otsuka/PhoreMost, Almirall/WuXi Biologics
Strong growth in Biocon's biologics segment continued in the second quarter and the vertical has now set a target of $1bn in annual sales by the 2021-22 fiscal year.